1. 2004
2. Cyhoeddwyd

   Pharmacoeconomic models that incorporate non-compliance

   Hughes, D. & Hughes, D. A., 1 Gorff 2004.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

3. Cyhoeddwyd

   Pharmacoeconomics appraisals by the all Wales medicines strategy group

   Hughes, D. & Hughes, D. A., 1 Gorff 2004.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

4. Cyhoeddwyd

   Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity

   Hughes, D., Hughes, D. A., Vilar, F. J., Ward, C. C., Alfirevic, A., Park, B. K. & Pirmohamed, M., 1 Meh 2004, Yn: Pharmacogenetics. 14, 6, t. 335-342

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

5. Cyhoeddwyd

   Patient compliance and persistence with prescribed medication: Measurement and health economic impact

   Hughes, D., Koncz, T., Hughes, D. A., Cleemput, I. & Annemans, L., 1 Mai 2004.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

6. Cyhoeddwyd

   Pharmacoeconomics in Wales: functions of the all Wales medicines strategy group

   Hughes, D. & Hughes, D. A., 1 Ebr 2004.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

7. Cyhoeddwyd

   Pharmacoeconomics of pharmacogenetic testing: azathioprine

   Hughes, D., McAllister, R. & Hughes, D. A., 1 Ebr 2004.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

8. Cyhoeddwyd

   Approaches to pharmacoeconomic analysis

   Hughes, D., Hughes, D. A., Walley, T. (gol.), Haycox, A. (gol.), Boland, A. (gol.) & Breckenridge, A. (gol.), 1 Ion 2004, Pharmacoeconomics. 2004 gol. Adis International, t. 101-126

   Allbwn ymchwil: Pennod mewn Llyfr/Adroddiad/Trafodion Cynhadledd › Pennod

9. Cyhoeddwyd

   Clinical Pharmacology: Special safety considerations in drug development and pharmacovigilance.

   Hughes, D., Atuah, K. N., Hughes, D. A. & Pirmohamed, M., 1 Ion 2004, Yn: Drug Safety. 27, 8, t. 535-554

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

10. Cyhoeddwyd

    Cost-effectiveness analysis of extended-release formulations of oxybutynin and tolterodine for the management of urge incontinence.

    Hughes, D., Hughes, D. A. & Dubois, D., 1 Ion 2004, Yn: Pharmacoeconomics. 22, 16, t. 1047-1059

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

11. Cyhoeddwyd

    Internationalisation of cost-effectiveness model for on-demand use of proton pump inhibitors - Belgium.

    Hughes, D. & Hughes, D. A., 1 Ion 2004, 2004 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

12. Cyhoeddwyd

    Modelling in health economics

    Hughes, D., Hughes, D. A., Walley, T. (gol.), Haycox, A. (gol.), Boland, A. (gol.) & Breckenridge, A. (gol.), 1 Ion 2004, Pharmacoeconomics. 2004 gol. Adis International, t. 141-154

    Allbwn ymchwil: Pennod mewn Llyfr/Adroddiad/Trafodion Cynhadledd › Pennod

13. Cyhoeddwyd

    The future challenges

    Hughes, D., Hughes, D. A., Walley, T. (gol.), Haycox, A. (gol.), Boland, A. (gol.) & Breckenridge, A. (gol.), 1 Ion 2004, Pharmacoeconomics. 2004 gol. Adis International, t. 167-174

    Allbwn ymchwil: Pennod mewn Llyfr/Adroddiad/Trafodion Cynhadledd › Pennod

14. 2003
15. Cyhoeddwyd

    Drug compliance and pharmaceconomics

    Hughes, D. & Hughes, D. A., 1 Rhag 2003.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

16. Cyhoeddwyd

    Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

    Hughes, D., Hughes, D. A. & Pirmohamed, M., 1 Tach 2003.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

17. Cyhoeddwyd

    Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

    Hughes, D., Hughes, D. A. & Pirmohamed, M., 1 Tach 2003, Yn: Value in Health. 6, 6, t. 749

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

18. Cyhoeddwyd

    Cost-utility analysis of on demand rabeprazole and esomeprazole for symptomatic gastro oesophageal reflux disease

    Hughes, D., Hughes, D. A. & Dubois, D., 1 Tach 2003, Yn: Value in Health. 6, 6, t. 613

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

19. Cyhoeddwyd

    Cost-utility analysis of on-demand rabeprazole and esomeprazole for non-erosive reflux disease

    Hughes, D. & Hughes, D. A., 1 Tach 2003.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

20. Cyhoeddwyd

    Cost-utility analysis of on-demand rabeprazole and esomeprazole for non-erosive reflux disease

    Hughes, D. & Hughes, D. A., 1 Tach 2003.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

21. Cyhoeddwyd

    Use of PK-PD modelling to predict the impact of non-compliance

    Hughes, D. & Hughes, D. A., 1 Tach 2003.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

22. Cyhoeddwyd

    Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

    Hughes, D., Hughes, D. A. & Pirmohamed, M., 1 Medi 2003.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

23. Cyhoeddwyd

    Modelling changes in first line antimalarial therapy

    Hughes, D. & Hughes, D. A., 1 Medi 2003.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

24. Cyhoeddwyd

    Predicting "real world" effectiveness by integrating adherence with pharmacodynamic modelling.

    Hughes, D., Hughes, D. A. & Walley, T., 1 Gorff 2003, Yn: Clinical Pharmacology and Therapeutics. 74, 1, t. 1-8

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

25. Cyhoeddwyd

    Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

    Hughes, D. & Hughes, D. A., 1 Meh 2003.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

26. Cyhoeddwyd

    Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

    Hughes, D. & Hughes, D. A., 1 Mai 2003.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

27. 2002
28. Cyhoeddwyd

    Accurate and practical dosing of African populations using a height, weight and age model designed for lapdap

    Hughes, D., Hughes, D. A. & Bagust, A., 1 Tach 2002.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur